Stablix
@stablix.com
Stablix is pioneering an entirely new field of targeted protein stabilization (TPS) to bring transformative medicines to patients with unmet medical need.
Stablix's Company Logos
Stablix's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#F38888
Froly
243, 136, 136
0, 82, 74
0, 44, 44, 5
#F0F0F0
Gallery
240, 240, 240
0, 0, 94
0, 0, 0, 6
#141416
Woodsmoke
20, 20, 22
240, 5, 8
9, 9, 0, 91
About Stablix
Stablix is a cutting-edge biotech brand that specializes in innovative drug discovery and development. With a team of highly experienced professionals, they are committed to targeting common vulnerabilities in diseases and creating novel therapeutic solutions. At the helm of Stablix is CEO Tony Kingsley, a seasoned industry leader who has successfully built and led organizations across various scientific disciplines and stages of drug development.
Dr. Eddine Saiah, the Chief Scientific Officer, brings over 25 years of experience in heading drug discovery and early development in both large pharmaceutical and small biotech companies. The team also includes Dr.
Brian Bowman, the Senior Vice President of Biology and Co-Founder, who has extensive expertise in protein biochemistry and molecular biology. Dr. Scott Kanner, the Associate Director of Platform Sciences and Co-Founder, specializes in targeting disease vulnerabilities and has a background in pharmacology and neuroscience.
Stablix is dedicated to developing innovative technologies and platforms for drug discovery. Their research and development efforts focus on advancing their groundbreaking platform technologies. Located in New York, Stablix is driven by a passion for improving global healthcare.
Reach out to them at info@stablix. com to learn more about their groundbreaking work
